These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1384815)

  • 1. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines.
    Hultsch T; Martin R; Hohman RJ
    Mol Biol Cell; 1992 Sep; 3(9):981-7. PubMed ID: 1384815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription.
    Hultsch T; Albers MW; Schreiber SL; Hohman RJ
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6229-33. PubMed ID: 1712484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.
    Bierer BE; Mattila PS; Standaert RF; Herzenberg LA; Burakoff SJ; Crabtree G; Schreiber SL
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9231-5. PubMed ID: 2123553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
    Fruman DA; Wood MA; Gjertson CK; Katz HR; Burakoff SJ; Bierer BE
    Eur J Immunol; 1995 Feb; 25(2):563-71. PubMed ID: 7533090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.
    Marx SO; Jayaraman T; Go LO; Marks AR
    Circ Res; 1995 Mar; 76(3):412-7. PubMed ID: 7532117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
    Hatfield SM; Mynderse JS; Roehm NW
    J Pharmacol Exp Ther; 1992 Jun; 261(3):970-6. PubMed ID: 1376361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells.
    Tsai M; Chen RH; Tam SY; Blenis J; Galli SJ
    Eur J Immunol; 1993 Dec; 23(12):3286-91. PubMed ID: 7504992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing immunosuppressant action with a nonnatural immunophilin ligand.
    Bierer BE; Somers PK; Wandless TJ; Burakoff SJ; Schreiber SL
    Science; 1990 Oct; 250(4980):556-9. PubMed ID: 1700475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.
    Kuo CJ; Chung J; Fiorentino DF; Flanagan WM; Blenis J; Crabtree GR
    Nature; 1992 Jul; 358(6381):70-3. PubMed ID: 1614535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.
    Heitman J; Movva NR; Hall MN
    Science; 1991 Aug; 253(5022):905-9. PubMed ID: 1715094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Ca2+ signaling in neutrophils by the mast cell-released immunophilin FKBP12.
    Bang H; Müller W; Hans M; Brune K; Swandulla D
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3435-8. PubMed ID: 7536932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural roles of immunophilins and their ligands.
    Sabatini DM; Lai MM; Snyder SH
    Mol Neurobiol; 1997 Oct; 15(2):223-39. PubMed ID: 9396011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte chemotactic activity of FKBP and inhibition by FK506.
    Leiva MC; Lyttle CR
    Biochem Biophys Res Commun; 1992 Jul; 186(2):1178-83. PubMed ID: 1379802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells.
    Fruman DA; Bierer BE; Benes JE; Burakoff SJ; Austen KF; Katz HR
    J Immunol; 1995 Feb; 154(4):1846-51. PubMed ID: 7530743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of new immunosuppressants.
    Halloran PF
    Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effect of rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2.
    Rebollo A; Mérida I; Gómez J; Pitton C; Silva A; Martínez C; García A
    Cytokine; 1995 Apr; 7(3):277-86. PubMed ID: 7543780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition.
    Flanagan WM; Crabtree GR
    Ann N Y Acad Sci; 1993 Nov; 696():31-7. PubMed ID: 8109837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells.
    Le Bihan S; Marsaud V; Mercier-Bodard C; Baulieu EE; Mader S; White JH; Renoir JM
    Mol Endocrinol; 1998 Jul; 12(7):986-1001. PubMed ID: 9658403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils.
    Hom JT; Estridge T
    Clin Immunol Immunopathol; 1993 Sep; 68(3):293-300. PubMed ID: 7690315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
    Brown EJ; Albers MW; Shin TB; Ichikawa K; Keith CT; Lane WS; Schreiber SL
    Nature; 1994 Jun; 369(6483):756-8. PubMed ID: 8008069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.